Psychometric properties of the Activities Scale for Kids-performance after allogeneic hematopoietic stem cell transplantation in adolescents and children : Results of a prospective study on behalf of the German-Austrian-Swiss GVHD Consortium.
AYAs
Cancer patients
GVHD
Physical functioning
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
19
02
2020
accepted:
11
03
2020
pubmed:
5
4
2020
medline:
30
1
2021
entrez:
5
4
2020
Statut:
ppublish
Résumé
The psychometric properties of an instrument, the Activity Scale for Kids-performance (ASKp), were assessed which was proposed to capture physical functioning after allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, this multicenter observational prospective study investigated the influence of clinical correlates focusing on chronic graft-versus-host disease (cGVHD). Patient-reported ASKp, clinician-reported Karnofsky/Lansky status (KPS/PSS), patient characteristics and cGVHD details were assessed of 55 patients with a median age of 12 years at baseline after day +100 post-HSCT and every 3 months during the next 18 months. The psychometric properties were evaluated and ASKp and KPS/PSS status was compared using ANOVAS and multiple regression models. The German version of the ASKp showed good psychometric properties except for ceiling effects. Discrimination ability of the ASKp was good regarding the need for devices but failed to predict cGVHD patients. Both the ASKp and the KPS/PSS were associated with patients after adoptive cell therapy being in need for devices, suffering from overlap cGVHD and from steroid side effects but not with patients' age and gender. In contrast to the KPS/PSS the ASKp only showed significant differences after merging moderate and severe cGHVD patients when comparing them to No-cGVHD (F = 4.050; p = 0.049), being outperformed by the KPS/PSS (F = 20.082; p < 0.001). The ASKp showed no clear advantages compared to KPS/PSS even though economical and patients' effort was higher. Further application range may be limited through ceiling effects. Both should be taken into consideration. Therefore, the results may not support the usage of ASKp after HSCT and rather suggest KPS/PSS, both patient and clinician reported.
Sections du résumé
BACKGROUND
BACKGROUND
The psychometric properties of an instrument, the Activity Scale for Kids-performance (ASKp), were assessed which was proposed to capture physical functioning after allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, this multicenter observational prospective study investigated the influence of clinical correlates focusing on chronic graft-versus-host disease (cGVHD).
METHODS
METHODS
Patient-reported ASKp, clinician-reported Karnofsky/Lansky status (KPS/PSS), patient characteristics and cGVHD details were assessed of 55 patients with a median age of 12 years at baseline after day +100 post-HSCT and every 3 months during the next 18 months. The psychometric properties were evaluated and ASKp and KPS/PSS status was compared using ANOVAS and multiple regression models.
RESULTS
RESULTS
The German version of the ASKp showed good psychometric properties except for ceiling effects. Discrimination ability of the ASKp was good regarding the need for devices but failed to predict cGVHD patients. Both the ASKp and the KPS/PSS were associated with patients after adoptive cell therapy being in need for devices, suffering from overlap cGVHD and from steroid side effects but not with patients' age and gender. In contrast to the KPS/PSS the ASKp only showed significant differences after merging moderate and severe cGHVD patients when comparing them to No-cGVHD (F = 4.050; p = 0.049), being outperformed by the KPS/PSS (F = 20.082; p < 0.001).
CONCLUSION
CONCLUSIONS
The ASKp showed no clear advantages compared to KPS/PSS even though economical and patients' effort was higher. Further application range may be limited through ceiling effects. Both should be taken into consideration. Therefore, the results may not support the usage of ASKp after HSCT and rather suggest KPS/PSS, both patient and clinician reported.
Identifiants
pubmed: 32246210
doi: 10.1007/s00508-020-01641-w
pii: 10.1007/s00508-020-01641-w
pmc: PMC7840624
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
41-51Commentaires et corrections
Type : ErratumIn
Références
Blood. 2019 Jul 18;134(3):304-316
pubmed: 31043425
Lancet. 2009 May 2;373(9674):1550-61
pubmed: 19282026
Curr Oncol Rep. 2018 Aug 3;20(9):74
pubmed: 30074106
Bone Marrow Transplant. 2016 Jan;51(1):13-26
pubmed: 26367233
Biol Blood Marrow Transplant. 2010 Dec;16(12):1707-17
pubmed: 20541028
J Child Health Care. 2014 Sep;18(3):207-14
pubmed: 23818145
Croat Med J. 2016 Jun 30;57(3):266-75
pubmed: 27374828
Bone Marrow Transplant. 2010 Apr;45(4):762-9
pubmed: 19784078
Biol Blood Marrow Transplant. 2012 Feb;18(2):162-71
pubmed: 22155139
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S371-82
pubmed: 22588758
J Clin Oncol. 1984 Mar;2(3):187-93
pubmed: 6699671
Br J Haematol. 2015 Nov;171(4):606-14
pubmed: 26304743
Pediatr Clin North Am. 2010 Feb;57(1):297-322
pubmed: 20307722
Blood. 2009 Jul 16;114(3):702-8
pubmed: 19470693
Haematologica. 2012 Mar;97(3):451-8
pubmed: 22058206
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
Biol Blood Marrow Transplant. 2015 Nov;21(11):1973-80
pubmed: 26234723
Blood. 2006 Oct 15;108(8):2867-73
pubmed: 16788100
Curr Hematol Malig Rep. 2015 Sep;10(3):183-91
pubmed: 26303672
Cancer. 1987 Oct 1;60(7):1651-6
pubmed: 3621134
Arch Phys Med Rehabil. 1995 Oct;76(10):913-8
pubmed: 7487430
Biol Blood Marrow Transplant. 2013 Jul;19(7):1073-80
pubmed: 23583827
Biol Blood Marrow Transplant. 2007 Oct;13(10):1207-15
pubmed: 17889358
Bone Marrow Transplant. 2014 Aug;49(8):1093-7
pubmed: 24820217
Ann Intern Med. 1997 Feb 1;126(3):184-92
pubmed: 9027268
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Haematologica. 2018 Sep;103(9):1535-1541
pubmed: 29858386
Bone Marrow Transplant. 2005 Jul;36(2):171-6
pubmed: 15937508
Biol Blood Marrow Transplant. 2006 Mar;12(3):252-66
pubmed: 16503494